Cell2cure ApS

3 trials Commercial sponsor Merged from 2 name variants

Filter these 3 trials by condition, phase, country and more.

Open in Search →

3 Registered trials

0 Recruiting

2 Completed trials

1 Countries active

1 Unique IMPs

100% Results reported

Phase II

Phase I/II

Phase I (Other)

Phase II: 1 Phase I/II: 1 Phase I (Other): 1

100%

2 of 2 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Autism spectrum disorder 1

Top IMPs

ALLOGENIC ADIPOSE-TISSUE-DERIVED MESENCHYMAL STEM CELLS 2

All trials

3 total

An open label safety and efficacy study of allogenic adipose tissue-derived mesenchymal stromal cells on autism and gastrointestinal symptom… Not authorised

2025-523699-21-00 Phase I (Other) 1 country ALLOGENIC ADIPOSE-TISSUE-DERIVED MESENCHYMAL STEM CELLS
Effect of mesenchymal stem cells on healing of foot ulcers in diabetes patients. A phase I pilot study. Ended

2023-505961-10-00 Phase I/II 1 country
ARIISE - ASCs in recently diagnosed non-ischemic heart failure Ended

2025-520837-22-00 Phase II 1 country ALLOGENIC ADIPOSE-TISSUE-DERIVED MESENCHYMAL STEM CELLS

Showing 1–3 of 3 trials

← All sponsors A–Z